Showing results (151-160 of 171) with videos related to
Sort By:
Pageof 18
Journal of the National Cancer Institute|January 25, 2022
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic ImplicationsTony El Jabbour, Maksym Misyura, Darren Cowzer, et al.Annals of Surgery|February 2, 2023
Waiting to Operate: The Risk of Salvage EsophagectomyThomas Boerner, Caitlin Harrington, Kay See Tan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2021
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) TrialKaryn A Goodman, Fang-Shu Ou, Nathan C Hall, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 27, 2009
NCCN task force: clinical utility of PET in a variety of tumor typesDonald A Podoloff, Douglas W Ball, Edgar Ben-Josef, et al.The Lancet. Oncology|September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialDaniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and PathwaysSmita Sihag, Samuel C Nussenzweig, Henry S Walch, et al.The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.Pageof 18